Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Non-corrective contacts

This article was originally published in The Gray Sheet

Executive Summary

Lack of a prescription requirement for non-corrective, colored contact lenses and aggressive marketing tactics by some firms are cited as a threat to public health in a Sept. 15 letter to HHS Secretary Tommy Thompson from Reps. Henry Waxman (D-Calif.) and John Boozman (R-Ark.). The congressmen seek Thompson's support for HR 2218 (co-sponsored by Waxman and Boozman), which would reverse FDA's April decision to regulate non-corrective contacts as cosmetics instead of devices, and ask Thompson to investigate marketing practices for the products (1"The Gray Sheet" Aug. 25, 2003, p. 8). The reps single out 2www.beWild.com for providing the lenses to teenagers without instructions or risk warnings and maintain that "it is imperative that these sales be halted as quickly as possible"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel